Defining Baseline Recurrence Risk in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor–Negative Early Breast Cancer: A Meta-Analysis of Endocrine Therapy Arms From Phase 3 Trials, Including the CDK4/6 Inhibitor Era

Purpose Patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) early breast cancer (EBC) are at risk of invasive recurrence despite standard endocrine therapy (ET). Prior meta-analyses largely reflect historical, lower-risk populations and may not capture recurrence patterns in contemporary, high-risk cohorts. This systematic literature review and meta-analysis evaluated risk of recurrence or death (ROR) with adjuvant ET ± chemotherapy across phase 3 randomized controlled trials (RCTs) from the past 2 decades, including recent cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) trials enrolling high-risk populations. Methods The search identified 19 phase 3 RCTs (2003–2024) reporting invasive disease-free survival/disease-free survival in patients with HR+/HER2 − EBC treated with ET ± chemotherapy. Pooled recurrence proportions at 3, 4, 5, 7, and 12 years were estimated using random-effects meta-analysis of proportions. Kaplan-Meier digitization analysis and meta-analysis among tumor characteristics and trial date subgroups were conducted. Results Nineteen RCTs (34 publications; >47,000 patients) met inclusion criteria. Among stage I-III patients receiving ET ± chemotherapy, pooled invasive ROR was 13% at 5 years and 27% at 12 years. At 4 years, ROR was 18% in stage II/III, 15% in node-positive, 11% in high-risk node-negative, and 7% in all-node-negative patients. Reconstructed survival curves showed a relatively constant hazard rate of ≈ 2%-3% per year through 12 years. Conclusions Phase 3 trials spanning aromatase inhibitor to CDK4/6i eras demonstrated substantial invasive ROR that emerged early and persisted through 12 years despite ET ± chemotherapy, underscoring the need for improved risk stratification and therapeutic strategy optimization beyond standard ET.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11434843/v1
Primary Topic
Breast Cancer Treatment Studies
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Defining Baseline Recurrence Risk in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor–Negative Early Breast Cancer: A Meta-Analysis of Endocrine Therapy Arms From Phase 3 Trials, Including the CDK4/6 Inhibitor Era

Giuseppe Curigliano, Peter Andreas Fasching, Dave Nellesen, Paolo Tarantino et al.
3 links
Research Square
Breast Cancer Treatment Studies
preprint

Defining Baseline Recurrence Risk in Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor–Negative Early Breast Cancer: A Meta-Analysis of Endocrine Therapy Arms From Phase 3 Trials, Including the CDK4/6 Inhibitor Era

Giuseppe Curigliano, Peter Andreas Fasching, Dave Nellesen, Paolo Tarantino, Olivia Shane, D Proudman, Vaidyanathan Ganapathy, Adrienne Kwok, Eva Ciruelos, Yen-Shen Lu, Erika Hamilton, Kevin Kalinsky, Corinth Auld, Nick McAndrew
preprint en

Abstract

Purpose Patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) early breast cancer (EBC) are at risk of invasive recurrence despite standard endocrine therapy (ET). Prior meta-analyses largely reflect historical, lower-risk populations and may not capture recurrence patterns in contemporary, high-risk cohorts. This systematic literature review and meta-analysis evaluated risk of recurrence or death (ROR) with adjuvant ET ± chemotherapy across phase 3 randomized controlled trials (RCTs) from the past 2 decades, including recent cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) trials enrolling high-risk populations. Methods The search identified 19 phase 3 RCTs (2003–2024) reporting invasive disease-free survival/disease-free survival in patients with HR+/HER2 − EBC treated with ET ± chemotherapy. Pooled recurrence proportions at 3, 4, 5, 7, and 12 years were estimated using random-effects meta-analysis of proportions. Kaplan-Meier digitization analysis and meta-analysis among tumor characteristics and trial date subgroups were conducted. Results Nineteen RCTs (34 publications; >47,000 patients) met inclusion criteria. Among stage I-III patients receiving ET ± chemotherapy, pooled invasive ROR was 13% at 5 years and 27% at 12 years. At 4 years, ROR was 18% in stage II/III, 15% in node-positive, 11% in high-risk node-negative, and 7% in all-node-negative patients. Reconstructed survival curves showed a relatively constant hazard rate of ≈ 2%-3% per year through 12 years. Conclusions Phase 3 trials spanning aromatase inhibitor to CDK4/6i eras demonstrated substantial invasive ROR that emerged early and persisted through 12 years despite ET ± chemotherapy, underscoring the need for improved risk stratification and therapeutic strategy optimization beyond standard ET.

Research Square
Harvard University (US), Emory University (US), University of California, Los Angeles (US), Sarah Cannon Research Institute (GB), Universitätsklinikum Erlangen (DE), Novartis (United States) (US), National Taiwan University Hospital (TW), Solti (ES), Comprehensive Cancer Center Erlangen (DE), European Institute of Oncology (IT), Analysis Group (United States) (US)
Novartis Pharmaceuticals Corporation
Good health and well-being
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon